MX2021015154A - Composicion farmaceutica parenteral de agonista dual de glp1/2. - Google Patents

Composicion farmaceutica parenteral de agonista dual de glp1/2.

Info

Publication number
MX2021015154A
MX2021015154A MX2021015154A MX2021015154A MX2021015154A MX 2021015154 A MX2021015154 A MX 2021015154A MX 2021015154 A MX2021015154 A MX 2021015154A MX 2021015154 A MX2021015154 A MX 2021015154A MX 2021015154 A MX2021015154 A MX 2021015154A
Authority
MX
Mexico
Prior art keywords
agonist
parenteral composition
pharmaceutical parenteral
dual glp1
glp1
Prior art date
Application number
MX2021015154A
Other languages
English (en)
Inventor
Lise Giehm
Alistair Vincent Gordon Edwards
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MX2021015154A publication Critical patent/MX2021015154A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas adecuadas para administración parenteral en sujetos humanos. En particular, la presente invención se refiere a composiciones farmacéuticas isotónicas para administración parenteral.
MX2021015154A 2019-06-14 2020-06-12 Composicion farmaceutica parenteral de agonista dual de glp1/2. MX2021015154A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19180233 2019-06-14
PCT/EP2020/066381 WO2020249782A1 (en) 2019-06-14 2020-06-12 Pharmaceutical parenteral composition of dual glp1/2 agonist

Publications (1)

Publication Number Publication Date
MX2021015154A true MX2021015154A (es) 2022-01-18

Family

ID=66867001

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021015153A MX2021015153A (es) 2019-06-14 2020-06-12 Composicion farmaceutica parenteral de agonista dual de glp1/2.
MX2021015154A MX2021015154A (es) 2019-06-14 2020-06-12 Composicion farmaceutica parenteral de agonista dual de glp1/2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021015153A MX2021015153A (es) 2019-06-14 2020-06-12 Composicion farmaceutica parenteral de agonista dual de glp1/2.

Country Status (14)

Country Link
US (2) US20230212227A1 (es)
EP (2) EP3982920A1 (es)
JP (2) JP2022535555A (es)
KR (2) KR20220020819A (es)
CN (2) CN113966225A (es)
AU (2) AU2020290014B2 (es)
BR (2) BR112021020941A2 (es)
CA (2) CA3138716A1 (es)
CL (2) CL2021003273A1 (es)
IL (2) IL286990A (es)
MX (2) MX2021015153A (es)
SG (2) SG11202111312UA (es)
WO (2) WO2020249782A1 (es)
ZA (1) ZA202107825B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022175410A1 (en) 2021-02-18 2022-08-25 Zealand Pharma A/S Composition for treating short bowel syndrome
KR20240058121A (ko) 2021-09-03 2024-05-03 질랜드 파마 에이/에스 투여 용법
CN116655772A (zh) * 2022-02-18 2023-08-29 成都奥达生物科技有限公司 一种长效的glp-1/glp-2双激动剂化合物
EP4323413A1 (en) * 2022-03-30 2024-02-21 Beijing QL Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof
WO2024061919A1 (en) * 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239364T3 (es) 1996-09-09 2005-09-16 Zealand Pharma A/S Sintesis de peptidos en fase solida.
US9453064B2 (en) 2012-05-03 2016-09-27 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
CN105849122B (zh) * 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
EP3212217A1 (en) 2014-10-31 2017-09-06 Gubra ApS Compositions and peptides having dual glp-1r and glp-2r agonist activity
WO2018104558A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
PE20191083A1 (es) 2016-12-09 2019-08-20 Zealand Pharma As Agonistas duales acilados de glp-1/glp-2

Also Published As

Publication number Publication date
CN113966226A (zh) 2022-01-21
WO2020249778A1 (en) 2020-12-17
AU2020293576A1 (en) 2021-11-04
JP2022535555A (ja) 2022-08-09
CN113966225A (zh) 2022-01-21
CA3138716A1 (en) 2020-12-17
CL2021003273A1 (es) 2022-07-22
MX2021015153A (es) 2022-01-18
US20230212227A1 (en) 2023-07-06
EP3982919A1 (en) 2022-04-20
ZA202107825B (en) 2024-02-28
KR20220020821A (ko) 2022-02-21
EP3982920A1 (en) 2022-04-20
BR112021024651A2 (pt) 2022-01-04
AU2020290014B2 (en) 2022-10-27
CA3138715A1 (en) 2020-12-17
AU2020290014A1 (en) 2021-11-04
JP2022535556A (ja) 2022-08-09
BR112021020941A2 (pt) 2021-12-21
SG11202111312UA (en) 2021-12-30
US20220202704A1 (en) 2022-06-30
SG11202111311WA (en) 2021-12-30
IL286990A (en) 2021-12-01
KR20220020819A (ko) 2022-02-21
WO2020249782A1 (en) 2020-12-17
IL286991A (en) 2021-12-01
CL2021003272A1 (es) 2022-07-22

Similar Documents

Publication Publication Date Title
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
JOP20220020A1 (ar) مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة
PH12015501858A1 (en) Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
MY189194A (en) Substituted tetrahydroquinolinone compounds as ror gamma modulators
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
MY181181A (en) Fgf21 derivatives and uses thereof
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX2020008125A (es) Composiciones que comprenden berberina.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
JOP20220093A1 (ar) تركيبة صيدلانية تشتمل على سيليكسيباغ
MX2023006281A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
AU2018279184A1 (en) Anti-TrkB antibodies
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
MX2023006280A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
MX2023006284A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
MX2022004014A (es) Composicion liofilizada que contiene 2-((s)-2-acetamido-3-(1h-indo l-3-il)propanamido)-6-diazo-5-oxohexanoato de (s)-isopropilo para administracion intravenosa y su uso.
MX2021015930A (es) Composiciones farmaceuticas para peptidos co-agonistas de glucagon y glp-1.